<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641276</url>
  </required_header>
  <id_info>
    <org_study_id>02621512.3.0000.5461</org_study_id>
    <nct_id>NCT01641276</nct_id>
  </id_info>
  <brief_title>Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma</brief_title>
  <acronym>THBC-HSL2</acronym>
  <official_title>Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Sirio-Libanes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is to identification of a group of specific amplitude-modulated
      frequencies of low intensity electromagnetic fields that is associated with biofeedback upon
      exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be exposed by different specific amplitude-modulated frequencies of low
      intensity electromagnetic fields for 30 min. During the exposure, autonomic response with be
      recorded in order to identify biofeedback response. Differences in group of frequencies is
      expected in patients with hepatitis B carries with or without hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response</measure>
    <time_frame>within 10 min of exposure</time_frame>
    <description>biofeedback response will be monitored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma</measure>
    <time_frame>within 10 minutes of exposure</time_frame>
    <description>Representation of autonomous response during the exposure of specific frequencies of modulation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatitis</condition>
  <condition>Hepatocellular Carcinomas</condition>
  <arm_group>
    <arm_group_label>hepatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hepatitis B carriers patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatocellular carcinoma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hepatites B carriers patients with associated hepatocellular carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low intensity amplitude-moduled electromagnetic fields</intervention_name>
    <description>Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.</description>
    <arm_group_label>hepatitis</arm_group_label>
    <arm_group_label>hepatocellular carcinoma patients</arm_group_label>
    <other_name>TheraBionic</other_name>
    <other_name>OncoBionic P1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatitis B carriers patients

          -  hepatitis B carriers patients with hepatocellular cancer patients

        Exclusion Criteria:

          -  other tumor types

          -  other hepatitis types
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederico P Costa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sirio-Libanes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sírio Libanês</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.nature.com/bjc/journal/v105/n5/full/bjc2011292a.html</url>
    <description>Results of a phase II study on patients with hepatocellular carcinoma</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sirio-Libanes</investigator_affiliation>
    <investigator_full_name>Frederico Perego Costa</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>biofeedback response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

